TJPC(SH:600488) Zheng Quan Zhi Xing·2025-07-11 08:10Core Viewpoint - The company, Tianyao Pharmaceutical Co., Ltd., anticipates a significant decline in net profit for the first half of 2025, projecting a decrease of 62.19% to 68.38% compared to the same period last year [1][2]. Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of approximately 44.9 million to 53.7 million yuan for the first half of 2025, a decrease of 88.32 million to 97.12 million yuan year-on-year [1][2]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be around 112 million to 121 million yuan, reflecting a year-on-year decrease of 18.59 million to 19.59 million yuan [1][2]. Group 2: Previous Year Performance - For the same period last year, the net profit attributable to shareholders was 142.02 million yuan [2]. - The basic earnings per share for the previous year were reported at 0.130 yuan [2]. Group 3: Reasons for Profit Decline - The decline in profit is attributed to the impact of the tenth batch of centralized procurement, which led to a decrease in the unit price of selected products, thereby reducing revenue and gross profit [2]. - The raw material pharmaceutical business faced intensified market competition, resulting in decreased sales volume and unit prices for certain products, further impacting revenue and profit [2].